Regeneron-1787 for Cutaneous Squamous Cell Carcinoma - Clinical Trial

What is the Purpose of this Study?

We are doing the study to understand how your body reacts to the study drug, Cemiplimab.
What is the Condition Being Studied?
Recurrent Cutaneous Squamous Cell Carcinoma (a type of skin cancer that keeps returning)

Who Can Participate in the Study?

Adults with Squamous Cell Carcinoma that keeps coming back.
-The lesion must be about a half inch to one inch across

Age Group
Adults

What is Involved?

If you choose to be in this study, you will:
-Get injected with the study drug (Cemiplimab) for 12 weeks
-Have a Blood draw
-Get a small biopsy of the skin
-Have an x-ray of your chest
-Give a urine sample

Study Details

Full Title
A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)
Principal Investigator
Protocol Number
IRB: PRO00101552
NCT: NCT03889912
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698